Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway (2022)

Peer-Reviewed Study · Jiang L; Sun YJ; Song XH; Sun YY; Yang WY; Li J; Wu YJ · 2022

Jiang L et al., 2022: Cell-line and xenograft study reporting that ivermectin inhibits colorectal and breast cancer cell motility and tumour metastasis through the Wnt/beta-catenin/integrin beta1/FAK axis; in the same paper ivermectin did not significantly inhibit primary subcutaneous tumour growth at 2 mg/kg.

Mechanistically, IVM suppressed the expressions of the migration-related proteins via inhibiting the activation of Wnt/β-catenin/integrin β1/FAK and the downstream signaling cascades.

n/a (HTML full text)

Jiang L et al., 2022: Cell-line and xenograft study reporting that ivermectin inhibits colorectal and breast cancer cell motility and tumour metastasis through the Wnt/beta-catenin/integrin beta1/FAK axis; in the same paper ivermectin did not significantly inhibit primary subcutaneous tumour growth at 2 mg/kg. Study type: cell lines + mouse metastasis and subcutaneous xenograft models. N: 3 mice/group (metastasis model) and 6 mice/group (subcutaneous model). Country: China (Institute of Zoology, Chinese Academy of Sciences). Dose: 1, 2 and 3 mg/kg/day intraperitoneal for 18 or 37 days; comparator: 0.9% NaCl vehicle. Funder: not stated in the retrieved record. Declared COI: 'None.' The paper itself reports: 'IVM had no obvious inhibitory effect on the growth of HCT-8 cells-derived primary subcutaneous tumor at the concentration of 2 mg/kg' – recorded here because it limits the anti-growth claim. Study type: animal.